Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Medical Developments International.
RELATED STOCKHEAD STORIES
Health & Biotech
Adherium’s focus on US market could pay off big time for its novel asthma device
Health & Biotech
ASX Health Stocks: MVP flies high after disclosing US ‘green whistle’ strategy, Imricor signs with prestigious Swiss hospital
Experts
CRITERION: Gains without pains? Maybe tackle these sporting injury stocks instead
Experts
ScoPo’s Powerplays: Taps on again with ASX health stocks in BIG capital raises
Experts
ScoPo’s Powerplays: ‘Big haircuts’ for ASX health stocks – Morgans reviews quarterly results
Health & Biotech
ASX Health Stocks: Emyria takes its MDMA-inspired drugs to the next level
Health & Biotech
Here are the Top 10 crucial trials coming up for ASX biotechs in 2022
Health & Biotech
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Health & Biotech
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
News
ASX Small Cap Lunch Wrap: Who’s looking for a ‘Tyrant Lizard Queen’ today?
Health & Biotech
ASX Health Stocks: MVP’s ‘green whistle’ has finally got to Phase 3 in the US after FDA decision
Health & Biotech
ASX Health Stocks: OncoSil up 15pc on German device funding; Starpharma expands to Middle East
Health & Biotech
Dr Boreham’s Crucible: Can fans of the ‘green whistle’ breathe easier as (if) Covid fades away?
Health & Biotech
Check Up: Fundie says ‘buy the dip’ as biotech loses shine amid pandemic rebound
Health & Biotech
Check Up: Paradigm targets Phase 3 clinical trial in the US; AI microbiology product fails to impress
Health & Biotech
ScoPo’s Powerplays: Market volatility creates both buying and selling opportunities in the Health sector
Health & Biotech
